Dose escalation, safety and immunogenicity study of a tetravalent meninogococcal polysaccharide diphtheria conjugate vaccine in toddlers

Pediatric Infectious Disease Journal

Volumn 21, Issue 10, 2002, Pages 978-979

  Rennels, Margaret ^a   King Jr , James ^a   Ryall, Robert ^a   Manoff, Susan ^a   Papa, Thomas ^a   Weddle, Andrea ^a   Froeschle, James ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

Children; Meningococcus; Safety; Vaccine immunogenicity

Indexed keywords

DIPHTHERIA VACCINE; TETRAMEND; TETRAVALENT MENINGOCOCCAL POLYSACCHARIDE DIPHTHERIA CONJUGATE VACCINE; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DOSE RESPONSE; FEVER; HUMAN; IMMUNOGENICITY; INFANT; INFECTION PREVENTION; INJECTION SITE; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; TREATMENT OUTCOME; VACCINE PRODUCTION;

EID: 0036799605     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200210000-00019     Document Type: Article

References (1)

1. Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1:992-1996. J Infect Dis 1999;180:1894-901.